Drug Profile
VX 25
Alternative Names: VX-25Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Vaccinex
- Class Antineoplastics; Cancer vaccines; Glycolipids; Immunoglobulin fragments; Immunoglobulin fusion proteins; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 09 Mar 2020 VX 25 is still in preclinical development in Cancer in USA (Parenteral)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)